Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DESTINY-Gastric02: Trastuzumab deruxtecan in HER2+ gastric/GEJ cancer
NCT04014075Phase 2Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Nov 2019
- Primary completion
- Nov 2021
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 5
01
Overview
A Phase 2 trial of trastuzumab deruxtecan in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Daiichi Sankyo Co., Ltd.. Started Nov 2019; status: completed.
02
Drugs
trastuzumab deruxtecan
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT04014075.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04014075.